RxDoctor Payments Data

Vinh Dang, MD

Family Medicine · Shenandoah, TXNPI 1679928089

Payments from drug & device makers

$2,383in general payments, 2019–2025

Across 107 payments — averaging $22.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$416
  • AstraZeneca$267
  • GSK$254
  • Lilly USA, LLC$235
  • Biohaven Pharmaceutical Holding Company Ltd.$234
  • Novo Nordisk$187
  • plus $789 from 18 others

What the payments were for

  • Food & beverage$2,383100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,383 in reported general payments places this provider in the 75th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$62,611
Medicare patients
221
Services billed
1,091

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide45$78,924
JardianceEmpagliflozin44$46,977
EliquisApixaban28$30,675
MounjaroTirzepatide14$20,232
Fluticasone-SalmeterolFluticasone Propion/Salmeterol15$5,266
Atorvastatin Calcium236$2,408
Esomeprazole Magnesium12$2,282
Tamsulosin Hcl80$2,087
Rosuvastatin Calcium147$1,757
Omeprazole94$1,412
Metoprolol Succinate79$1,402
Levothyroxine Sodium147$1,294
SynthroidLevothyroxine Sodium23$1,257
Losartan Potassium106$1,142
Albuterol Sulfate HfaAlbuterol Sulfate41$1,088

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$187$78,92445 claims
Boehringer IngelheimJardiance$18$46,97744 claims
PfizerEliquis$185$30,67528 claims
Lilly USA, LLCMounjaro$235$20,23214 claims
AbbVieSynthroid$416$1,25723 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Shenandoah

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →